Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
PEG-MGF (PEGMGF) is a muscle peptide, at the research chemical stage in the published literature. PEGylated version of MGF with dramatically extended half-life, allowing systemic rather than site-specific effects.
PEGylated version of MGF with dramatically extended half-life, allowing systemic rather than site-specific effects.
| Research Status | Research chemical |
|---|---|
| Half-Life | Several days |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 200 mcg 2-3x per week |
Same as MGF with PEG attachment for extended circulation time and systemic distribution.
PEGylated version of MGF with dramatically extended half-life, allowing systemic rather than site-specific effects.
Same as MGF with PEG attachment for extended circulation time and systemic distribution.
PEG-MGF is at the following stage in the published literature: Research chemical. All information is for research and educational purposes only.
Reported half-life: Several days.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.